Ipamorelin: A Selective GH Secretagogue With Strong Theory and Thin Human Proof

Overview

Ipamorelin is one of the most talked-about "growth hormone (GH) peptides" in the self-experimentation world, and for an unusual reason: its core scientific claim is genuinely well supported, while its real-world payoff is not. It is a synthetic pentapeptide that mimics ghrelin and triggers a clean pulse of growth hormone — without the cortisol, prolactin or appetite spikes seen with older peptides in its class [1].

That selectivity is real and reproducible in the lab. What is missing is evidence that it does anything useful in people. The only published human efficacy trial — in surgical patients — found ipamorelin no better than placebo [3]. There is no approved product, no validated human dose for any goal, and most of the supporting data comes from rats, pigs, fish and ferrets. So the honest summary is: strong mechanism, one decent human pharmacology study, and one failed human outcome trial. Read on with that asymmetry firmly in mind.

What it is & how it works

Ipamorelin (sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2) is a five-amino-acid peptide that acts as a ghrelin mimetic. It binds and activates the growth hormone secretagogue receptor (GHS-R1a) — the ghrelin receptor — a G-protein-coupled receptor sitting on the GH-producing somatotroph cells of the pituitary gland. Activating it prompts the pituitary to release a pulse of its stored growth hormone, which in turn can raise downstream IGF-1 [1].

The defining feature is selectivity. Earlier growth-hormone-releasing peptides (GHRP-2, GHRP-6, hexarelin) also raise GH, but they tend to drag the stress axis along with them — bumping ACTH and cortisol, and sometimes prolactin. In the original 1998 characterisation, ipamorelin released GH about as potently as GHRP-6 yet did not raise ACTH or cortisol even at doses more than 200 times its GH-releasing ED50, and did not move prolactin, FSH, LH or TSH [1]. That makes its hormonal "fingerprint" look more like GHRH (the body's own GH-releasing hormone) than like the other GHRPs.

Importantly, ipamorelin works through the ghrelin-receptor pathway, which is distinct from the GHRH pathway. Because the two routes are separate, they can act additively — the mechanistic basis for why people pair a GHRP with a GHRH analogue (more on that below). The GHS-R1a receptor also appears in the gut, where ipamorelin acts via cholinergic excitatory enteric neurons to speed gastric emptying and motility in rodent models [5] — the rationale behind its (ultimately unsuccessful) trial in post-surgical gut paralysis.

What the published research says

Mechanism and selectivity (preclinical, strong). The 1998 Novo Nordisk study established ipamorelin as the first selective GH secretagogue, releasing GH in rat pituitary cells, whole rats and swine without activating the stress axis [1]. This selectivity claim is the most robustly supported thing about the compound.

Human pharmacology (one supportive study). A dose-escalation study in 32 healthy men, using single intravenous infusions, found dose-proportional kinetics, a half-life of roughly two hours, and a clear single episode of GH release at every dose tested [2]. So in humans it demonstrably does the one thing it is designed to do: it releases GH.

Human efficacy (one trial, negative). This is the crux. A Phase 2 double-blind randomised controlled trial (NCT00672074) enrolled 114 bowel-resection patients and gave intravenous ipamorelin at 0.03 mg/kg twice daily for up to seven days. It was well tolerated — but it did not beat placebo on the main endpoint, time to first tolerated meal (25.3 vs 32.6 hours, p=0.15), nor on any secondary endpoint [3]. The trial was arguably underpowered, but the headline stands: the only published human outcome study was negative.

Animal models (the bulk of the evidence). The preclinical literature is broader and more encouraging, which is worth keeping in proportion:

• Gut motility: In rats with surgical ileus, ipamorelin shortened time to first bowel movement and, with repeated dosing, increased food intake and weight gain [4]; it also reversed delayed gastric emptying and impaired smooth-muscle contractility via the ghrelin-receptor pathway [5].
• Bone: In rats it dose-dependently increased tibial longitudinal growth — notably without changing total IGF-1 or bone turnover markers [6] — and over 12 weeks raised bone mineral content by increasing bone size, though volumetric bone density was unchanged [7].
• Anti-catabolic effects: In glucocorticoid-treated rats, ipamorelin counteracted steroid-induced loss of muscle strength and roughly quadrupled periosteal bone formation [8], preserved the GH/IGF-1 response despite steroids [9], and partially reversed steroid-induced nitrogen wasting — though less effectively than GH itself [10].
• Cachexia: In ferrets, ipamorelin reduced cisplatin-induced weight loss by about a quarter in the delayed phase, but had no anti-nausea effect [11].

The throughline: consistent, biologically plausible animal signals for growth, bone and anti-catabolic effects — and one human trial that did not translate.

Regulatory status. Ipamorelin is not approved by the FDA or any major regulator for any indication. It reached Phase 2, failed to show efficacy, and was not advanced [3]. It is on the WADA Prohibited List as a growth hormone secretagogue and is detectable in urine [12]. In the US it is sold "research-use-only". Its compounding position is unusual, and reading half of it gives the wrong answer: the FDA lists ipamorelin acetate in both of its category 2 tables. It sits in the active category 2 table under the 503B interim policy, added 29 September 2023, and it also appears among nominated-but-withdrawn substances — where the FDA states expressly that it still appears in the active table because it is in category 2 under 503B. So the listing is current, not historical. Category 2 means the agency has identified the substance as potentially presenting significant safety risks in compounding; here those are possible immunogenicity from aggregation or peptide-related impurities, unnatural amino acids that complicate characterisation, published serious adverse events including death when ipamorelin was given intravenously for gastric motility, and an absence of safety information for certain other injectable routes [13].

Dose & Exposure Context

Members only

Detailed exposure data is available to members

Research Rats reports dose and exposure figures as evidence context, not use instructions. The detailed section sets out what quantities were licensed, studied, or reported, each tied to its source:

• Regulated Prescribing Context
• Human Clinical Exposure
• Preclinical Exposure
• Community-Reported Exposure Patterns
• Interpretation

Regulatory status, evidence strength and safety context above remain public.

Sign in or create an account

Safety & considerations

In the single Phase 2 human trial, intravenous ipamorelin at 0.03 mg/kg twice daily was reported as well tolerated, with adverse-event rates similar to placebo [3]. That is reassuring as far as it goes — but it covers a short, supervised hospital course in surgical patients, not chronic self-injection, and the same trial showed no benefit [3].

A note on the selectivity claim that underpins ipamorelin's whole reputation: the low-cortisol, low-prolactin profile comes mainly from swine and rodent work [1]. It is plausible and partly supported by the human pharmacology data, but it has not been exhaustively confirmed across every human dose and condition.

The bottom line

Ipamorelin is a genuinely interesting molecule: the first GH secretagogue shown to release growth hormone with GHRH-like selectivity, sparing the stress and prolactin axes [1], and it demonstrably releases GH in humans [2]. That is the strong part of the story.

The weak part is everything downstream. The only published human efficacy trial failed [3]. Almost all the encouraging signals — bone growth, anti-catabolic effects, gut motility — are from rats, pigs and ferrets [4, 5, 6, 7, 8, 9, 10, 11]. There is no approval, no validated human dose, and an unsettled regulatory and compounding status [13]. The community's belief that "raises GH, therefore works" is exactly the inference the human evidence has not supported. If you are weighing ipamorelin, treat the mechanism as well established and the benefits as unproven — and speak to a qualified clinician before doing anything.